William E. Delaney - Concepedia

Author

William E. Delaney

Also Known As

W Delaney, W E Delaney, W. Delaney, W. E. Delaney, W.E. Delaney, WILLIAM E. DELANEY, William Delaney, William Delaney IV, William Delaney Iv, William E Delaney

154

Publications

6.7K

Citations

H-Index

130

Concepts

All Affiliations

Gilead Sciences (United States)Pennsylvania State University Victorian Infectious Diseases Reference Laboratory Penn State Milton S. Hershey Medical Center

About

William E. Delaney is an author at Gilead Sciences (United States) specializing in medicine, hepatitis, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	56	4.3K
2	Natural Sciences	10	11	703
3	Engineering	3	3	58
4	Health Sciences	3	3	164
5	Arts	1	1	33

William E. Delaney

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆ Bettina Werle–Lapostolle, Scott Bowden, Stephen Locarnini, Gastroenterology Hepatitis DHepatologyHepatitis CViral HepatitisLiver Physiology	2004	895
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase Peter Angus, Rhys Vaughan, Shelly Xiong, Gastroenterology Novel MutationMolecular VirologyPathogenesisImmunologyDipivoxil Therapy	2003	567
The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro William E. Delaney, Huiling Yang, Christopher Westland, Journal of Virology	2003	259
Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus William E. Delaney, Adrian S. Ray, Huiling Yang, Antimicrobial Agents and Chemotherapy ImmunologyHepatitis BCell CultureHbv PolymeraseAntiviral Drug	2006	255
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1 1Gilead Sciences gratefully acknowledges the patients, investigators, and study site personnel who participated in clinical trials GS-98-437 and GS-98-438. C. Westland, William E. Delaney, Huiling Yang, Gastroenterology Site PersonnelHepatologyViral HepatitisHepatitis BHepatitis	2003	223
<i>In Vitro</i> Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents Xiaoping Qi, Shelly Xiong, Huiling Yang, Antiviral Therapy	2007	178
Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV Huiling Yang, Xiaoping Qi, Alex Sabogal, Antiviral Therapy Viral HepatitisMedicineImmunologyAntiviral Drug DevelopmentMolecular Biology	2005	170
Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks Huiling Yang, Christopher Westland, William E. Delaney, Hepatology	2002	169
Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In Vitro William E. Delaney, Ros Edwards, Danni Colledge, Antimicrobial Agents and Chemotherapy	2002	156
The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection Congrong Niu, Christine M. Livingston, Li Li, PLoS ONE Viral ReplicationViral PathogenesisImmunologyInnate ImmunityViral Persistence	2017	149

Page 1